Key Takeaway: Cognition Therapeutics has published a manuscript regarding its oral drug candidate, Zervimesine, aimed at treating dry Age-related Macular Degeneration (AMD). The publication details the drug's potential and its development process. However, the article does not provide specific results or findings from the study.
Price reaction · baseline $0.4549 (2025-02-28 close) · clean, no other CGTX news in the window
day 0 close
-5.4%
day 1 · peak
-7.5%
day 3
-5.2%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
You are now leaving the Cognition Therapeutics website
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.